Microinduction to Buprenorphine from Methadone for Chronic Pain: Outpatient Protocol with Case Examples.
Marcelina Jasmine SilvaZhanette CoffeeJessica GozaKelly RumrillPublished in: Journal of pain & palliative care pharmacotherapy (2022)
The negative sequelae of full mu agonist chronic opioid analgesic therapy (COAT) are numerous and well documented. One safer alternative to COAT use in chronic, non-cancer pain (CNCP) is a transition to buprenorphine. However, transitioning patients from methadone COAT regimens can be challenging due to the pharmacodynamics of buprenorphine, as well as to the limited commercial formulations of buprenorphine available, and their restrictive instructions for use. Presented here are clinical cases transitioned to buprenorphine from methadone via a novel microinduction protocol during enrollment in an outpatient, group, integrative, multidisciplinary program. The protocol was successful to promote satisfactory and sustained COAT cessation for patients with CNCP and is arguably safer than current conventional practices.
Keyphrases
- chronic pain
- pain management
- randomized controlled trial
- end stage renal disease
- chronic kidney disease
- ejection fraction
- quality improvement
- primary care
- newly diagnosed
- neuropathic pain
- papillary thyroid
- healthcare
- health insurance
- spinal cord injury
- patient reported outcomes
- squamous cell carcinoma
- bone marrow
- spinal cord
- anti inflammatory
- cell therapy
- smoking cessation
- lymph node metastasis